Halozyme Therapeutics, Inc. HALO
Composite 58/100; the shares have moved about 41% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 31/100 — a moderate mark against it.
Quality ranks 77/100 — a strong point in its favour. Momentum ranks 72/100 — a moderate point in its favour. Balance-sheet strength ranks 64/100 — a moderate point in its favour.
Valuation ranks 31/100 — a moderate mark against it. Growth ranks 47/100 — a slight mark against it.
What the company does Halozyme Therapeutics (HALO) commercializes recombinant human hyaluronidase (rHuPH20), enabling subcutaneous delivery of biologics and small molecules. Key products include Hylenex (subcutaneous drug dispersion), XYOSTED (testosterone therapy), and partnered SC formulations like Herceptin Hylecta and Phesgo for oncology.
Key financials HALO shows strong profitability with ROE 99.4%, ROA 22.1%, and net margins 23.1%. Revenue grew 42.2% and EPS 31.2%, supported by gross margins of 76.7%. However, debt/equity is elevated at 9.91x, and net debt/EBITDA stands at 1.95x.
Stock health Momentum is robust: 12-month return 41.07%, RSI(14) 68.30 (near overbought), and trading -1.35% below its 52-week high. Sideravia scores Quality 80.7 and Momentum 73.7, indicating strong fundamentals and positive sentiment.
Price vs fair value HALO trades at a **discount** of 150.00% to our fair-value estimate of 208.25 and a **discount** of 4.31% to the 12-month target of 86.89. - IBD flags a “buy zone” rebound (Investor’s Business Daily, 2026-07-29). - Forward PEG of 0.07 and Fwd P/E of 11.35 suggest undervaluation relative to growth (Valuation percentile 37.1/100). - Analyst count of 9.0 supports near-term target alignment.
Looking forward With a rich pipeline and expanding SC partnerships, HALO’s valuation gap may reflect near-term execution risk. Forward metrics imply potential rerating if revenue growth sustains above 40%. Monitor pipeline catalysts and margin stability.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.